No Additional Benefit From Switching to Bevacizumab, Exemestane in Breast Cancer

Share this content:
Maintenance bevacizumab plus exemestane did not achieve longer progression-free survival.
Maintenance bevacizumab plus exemestane did not achieve longer progression-free survival.

Maintenance bevacizumab plus exemestane (E+BEV) for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who did not progress after treatment with taxane plus bevacizumab (T+BEV) did not achieve longer progression-free survival, according to a study published in Annals of Oncology.1

Researchers led by Olivier Trédan, MD, PhD, of Centre Léon Bérard in Lyon, France, conducted a prospective, open-label, phase 3 study of 117 patients with histologically confirmed ER-positive, HER2-negative metastatic breast cancer and non-progressive disease after 16 to 24 weeks of T+BEV.

Patients were randomized to either continuation of T+BEV or maintenance E+BEV, with primary end point being progression-free survival from randomization.

Interim analysis of 98 patients showed that the probability of reaching a statistically significant improvement in progression-free survival was only 7%, leading the Independent Data and Monitoring Committee to recommend termination of patient enrollment.

After median follow-up of 21 months for all patients, 6-month progression-free survival was 53.6% with T+BEV and 55.2% with E+BEV. Median progression-free survival from BEV initiation was 12.5 months for T+BEV and 12.3 months with E+BEV.

Updated data after a median follow-up of 35 months showed death rates of 44% with T+BEV and 55% with E+BEV.


1. Trédan O, Follana P, Moullet I, et al. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study [published online ahead of print February 24, 2016]. Ann Oncol. doi:10.1093/annonc/mdw077.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs